Lenalidomide Enhances CAR-T Cell Activity Against Solid Tumor Cells

Chimeric antigen receptor (CAR) T-cell immunotherapy still faces many challenges in the treatment of solid tumors, one of which is T-cell dysfunction or exhaustion. Immunomodulator lenalidomide may improve CAR T-cell function. In this study, the effects of lenalidomide on CAR T-cell functions (cytot...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Transplant
Main Authors: Wang, Zhixiong, Zhou, Guomin, Risu, Na, Fu, Jiayu, Zou, Yan, Tang, Jiaxing, Li, Long, Liu, Hui, Liu, Qian, Zhu, Xuekai
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2020
Assuntos:
Cancer Pharmacogenomics and Target Therapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7784582/
https://ncbi.nlm.nih.gov/pubmed/32967454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0963689720920825
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados